Form 8-K - Current report:
SEC Accession No. 0001493152-21-013073
Filing Date
2021-05-27
Accepted
2021-05-27 16:31:56
Documents
18
Period of Report
2021-05-21
Items
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm 8-K 54397
2 ex99-1.htm EX-99.1 14684
3 ex99-1_001.jpg GRAPHIC 48633
4 ex99-1_002.jpg GRAPHIC 176694
5 ex99-1_003.jpg GRAPHIC 119658
6 ex99-1_004.jpg GRAPHIC 161761
7 ex99-1_005.jpg GRAPHIC 171133
8 ex99-1_006.jpg GRAPHIC 139532
9 ex99-1_007.jpg GRAPHIC 128877
10 ex99-1_008.jpg GRAPHIC 171084
11 ex99-1_009.jpg GRAPHIC 192008
12 ex99-1_010.jpg GRAPHIC 138043
13 ex99-1_011.jpg GRAPHIC 123738
14 ex99-1_012.jpg GRAPHIC 118842
15 ex99-1_013.jpg GRAPHIC 162489
16 ex99-1_014.jpg GRAPHIC 149600
17 ex99-1_015.jpg GRAPHIC 130716
18 ex99-1_016.jpg GRAPHIC 180665
  Complete submission text file 0001493152-21-013073.txt   3257630
Mailing Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118
Business Address 3150 ALMADEN EXPRESSWAY, SUITE 250 SAN JOSE CA 95118 408-708-9808
Anixa Biosciences Inc (Filer) CIK: 0000715446 (see all company filings)

EIN.: 112622630 | State of Incorp.: DE | Fiscal Year End: 1031
Type: 8-K | Act: 34 | File No.: 001-37492 | Film No.: 21973164
SIC: 2834 Pharmaceutical Preparations